Skip to main
CVSA

CVSA Stock Forecast & Price Target

CVSA Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Covista is projected to have increased revenue and earnings, led by their successful Chamberlain/Walden segments and a strong EBITDA performance from their CVSA division. There are some potential risks, but their focus on clinical healthcare, partnerships, and expansion plans make them well-positioned for future growth. Despite being undervalued, the company has a strong executive team and a new growth strategy, making it an "OUTPERFORM" investment with a target price of $170.

Bears say

Covista is a for-profit healthcare education company facing challenges with declining enrollments in its nursing segment, Chamberlain, and potential liabilities from its former subsidiary, DeVry University. While there may be some signs of improvement, there are risks to the company's outlook, including increased competition and the possibility of regulatory changes. Additionally, the stock has underperformed due to concerns about the Chamberlain segment, and there is uncertainty around the success of its turnaround plan. Financially, the company has shown strong recent performance, with guidance for continued growth, but there are downside risks to consider. Overall, the company's outlook is negative, with potential for continued underperformance and challenges for its business model.

CVSA has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Adtalem Global Education Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Adtalem Global Education Inc (CVSA) Forecast

Analysts have given CVSA a Buy based on their latest research and market trends.

According to 2 analysts, CVSA has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $155, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $155, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Adtalem Global Education Inc (CVSA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.